Pomerantz Law Firm Issues Warning to Investors of Replimune Group Over Class Action Lawsuit

Investor Alert: Pomerantz Law Firm and Replimune Group, Inc.

Pomerantz LLP has recently announced a significant class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). This lawsuit has important implications for investors who have experienced losses due to their investment in Replimune. The firm is urging affected investors to initiate contact for participation in the action before the approaching deadline.

The lawsuit primarily concerns allegations of securities fraud and other unlawful business practices conducted by Replimune and certain individuals in leadership positions within the company. Investors who have purchased or acquired Replimune securities during the relevant period are encouraged to reach out to attorney Danielle Peyton, who is handling the case, by calling 646-581-9980 or emailing [email protected] Essential information such as mailing addresses and telephone numbers should be included for proper processing of inquiries.

The timeline for involvement is critical. Investors have until September 22, 2025, to request that the court appoint them as Lead Plaintiff in the class action. Full details, including a copy of the Complaint, can be found on Pomerantz's official website at www.pomerantzlaw.com.

On July 22, 2025, Replimune made headlines when it issued a press release revealing that the U.S. Food and Drug Administration (FDA) had dispatched a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for the innovative treatment known as RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. The letter explicitly pointed out that the FDA deemed the BLA inadequate for approval in its current state, primarily indicating that the IGNYTE trial did not constitute a sufficiently robust clinical investigation to validate effectiveness.

Furthermore, the FDA highlighted challenges regarding the trial's results, attributing it to the diverse characteristics of the patient cohort involved. Linked to these concerns, the FDA identified multiple items within the study's design of the confirmatory trial that require attention, although it was noted that no significant safety issues were indicated.

In direct response to this adverse news, Replimune's stock price plummeted. Following the announcement, the stock lost a staggering $9.52 per share or about 77.24%, closing at a mere $2.81. This dramatic decline illustrates the far-reaching effects of the FDA's communication on investor confidence and stock value.

Pomerantz LLP is considered one of the leading firms in corporate, securities, and antitrust class action litigation. With a history spanning over 85 years, the firm was founded by Abraham L. Pomerantz, who played a vital role in the development of securities class action law. The firm has consistently supported victims of securities fraud and has obtained numerous monumental settlements on behalf of class members. For more information on Pomerantz's advocacy and past successes, visit www.pomlaw.com.

As the deadline for investors approaches, swift action could be critical. Shareholders of Replimune Group, Inc. should weigh their options and act accordingly if they seek to join this class action lawsuit to ensure their voices are heard and their interests protected.